Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antineoplaston A10 and AS2-1 in Non-Hodgkin's Lymphoma
NCT00003500Phase 2Terminated
- Sponsor
- Burzynski Research Institute
- Start
- Mar 1996
- Primary completion
- Jun 2000
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of antineoplaston A10 and antineoplaston AS2-1 in non-Hodgkin lymphoma (NHL), sponsored by Burzynski Research Institute. Primary endpoints: Objective Response Rate at 12 months and Safety and Tolerance at 12 months. Started Mar 1996; status: terminated.
02
Drugs
antineoplaston A10antineoplaston AS2-1
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00003500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003500.